Judah Frommer

Q: What is Judah Frommer's success rate?

Judah Frommer currently has a success rate of 77.21071763071575.

Q: What is the average return of Judah Frommer's calls?

Their stock ratings have generated an average return of 28.69048715395015.

Morgan Stanley | Healthcare

Judah Frommer is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1158 out of 4738 analysts, they have issued 25 stock ratings with a success rate of 77.21% and an average return of 28.69%.

Judah Frommer has a well-established track record, with 25 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 77.21% and an average return of 28.69%, underscoring their expertise and ability to identify winning opportunities for investors.

#1158

Out of 4738

Total Ratings

+77.21%

Success Rate

+28.69%

Average Return

Recent Ratings Analysis

CLDX

Buy

Jul 22, 2026

Target

$40.00

Current

$34.77

Performance

0.00%

Judah Frommer rated CLDX as Overweight on Jul 22, 2026, setting a price target of 40. Shares have remained stable near 34.77, leaving the 40 target still in play.

CMPS

Buy

Jul 07, 2026

Target

$17.00

Current

$11.93

Performance

-8.16%

On Jul 07, 2026, CMPS was given a Overweight rating by Judah Frommer, with a target price of 17. Despite the Buy call, shares fell from 11.93 to 11.93, challenging the optimistic stance.

EVMN

Buy

Jun 30, 2026

Target

$26.00

Current

$11.40

Performance

-14.22%

EVMN received a Overweight rating from Judah Frommer on Jun 30, 2026, aiming for 26. The rating hasn’t played out as hoped, with the stock trading 14.22% below expectations.

ABVX

Buy

Jun 02, 2026

Target

$132.00

Current

$129.73

Performance

—

On Jun 02, 2026, Judah Frommer published a Overweight outlook on ABVX, with a target of 132. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 129.73.

AVLN

Buy

May 26, 2026

Target

$53.00

Current

$28.72

Performance

7.57%

Judah Frommer on May 26, 2026 assigned AVLN a Overweight rating, with a price target of 53. The Buy call aligned well with market performance, producing a gain of 7.57%.

ZBIO

Hold

May 14, 2026

Target

$22.00

Current

$31.49

Performance

66.61%

On May 14, 2026, Judah Frommer reaffirmed ZBIO with a Equal-Weight rating, targeting 22. Market strength beyond 31.49 went further than the conservative outlook suggested.

BCAX

Buy

May 12, 2026

Target

$37.00

Current

$27.96

Performance

24.93%

BCAX was rated Overweight by Judah Frommer on May 12, 2026, with a price objective of 37. A bullish response from the market helped close the gap of 9.04 to the target.

KLRS

Buy

Apr 16, 2026

Target

$14.00

Current

$4.07

Performance

-38.24%

On Apr 16, 2026, Judah Frommer initiated coverage on KLRS with a Overweight rating and target of 14. The Buy call has yet to be validated as shares remain 9.93 away from the target.

IMMX

Buy

Mar 25, 2026

Target

$20.00

Current

$9.41

Performance

5.61%

Judah Frommer issued a Overweight recommendation for IMMX on Mar 25, 2026, price target set at 20. Investors following the Buy call captured upside momentum, with shares now at 9.41.

TRVI

Buy

Mar 18, 2026

Target

$18.00

Current

$17.36

Performance

62.39%

On Mar 18, 2026, TRVI was evaluated by Judah Frommer, who gave a Overweight rating and target of 18. This case illustrates how a timely bullish rating can translate into tangible gains of 62.39%.

RGNX

Buy

Mar 06, 2026

Target

$18.00

Current

$10.20

Performance

17.92%

Judah Frommer rated RGNX as Overweight on Mar 06, 2026, setting a price target of 18. The call has proven timely, with shares rising 17.92% toward the price target of 18.

BLTE

Buy

Mar 03, 2026

Target

$201.00

Current

$157.14

Performance

-6.40%

On Mar 03, 2026, BLTE was given a Overweight rating by Judah Frommer, with a target price of 201. Despite the Buy call, shares fell from 157.14 to 157.14, challenging the optimistic stance.

AGMB

Buy

Mar 03, 2026

Target

$28.00

Current

$11.60

Performance

-27.04%

AGMB received a Overweight rating from Judah Frommer on Mar 03, 2026, aiming for 28. The rating hasn’t played out as hoped, with the stock trading 27.04% below expectations.

GMAB

Hold

Feb 16, 2026

Target

$34.00

Current

$28.85

Performance

—

On Feb 16, 2026, Judah Frommer published a Equal-Weight outlook on GMAB, with a target of 34. Sideways action left the Hold view intact, with no major move since 28.85.

APLS

Hold

Jul 02, 2025

Target

$26.00

Current

$41.03

Performance

130.25%

Judah Frommer on Jul 02, 2025 assigned APLS a Equal-Weight rating, with a price target of 26. Shares outperformed expectations, climbing 130.25% despite the neutral view.

BPMC

Hold

Jun 05, 2025

Target

$129.00

Current

$129.46

Performance

1.22%

On Jun 05, 2025, Judah Frommer reaffirmed BPMC with a Equal-Weight rating, targeting 129. The neutral call matched muted market action of 1.22%.

GLPG

Sell

Feb 14, 2025

Target

$22.00

Current

$27.98

Performance

9.98%

GLPG was rated Underweight by Judah Frommer on Feb 14, 2025, with a price objective of 22. Bearish sentiment was justified as the stock retreated to 27.98.

FDMT

Sell

Jan 13, 2025

Target

$6.00

Current

$10.96

Performance

130.25%

On Jan 13, 2025, Judah Frommer initiated coverage on FDMT with a Underweight rating and target of 6. The rating correctly identified downside risks, with the stock losing 130.25%.

Frequency Asked Questions

Who is Judah Frommer?

Judah Frommer is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Judah Frommer's success rate?

Judah Frommer currently has a success rate of +77.21%.

How many ratings has Judah Frommer issued?

Judah Frommer has issued 25 stock ratings so far.

What is the average return of Judah Frommer's calls?

Their stock ratings have generated an average return of +28.69%.

What is Judah Frommer's ranking?

Judah Frommer is ranked #1158 out of 4738 analysts.

What types of ratings does Judah Frommer give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Judah Frommer?

You can follow Judah Frommer by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Judah Frommer?

Their latest rating was a Buy on CLDX issued on 2026-07-22.